<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Brain tumours are the most common solid tumours that afflict the pediatric population. Me-dulloblastoma (MB) is the most common malignant brain tumour in children, constituting nearly 20% of all pediatric brain tumours. This study is an evaluation of overall survival rate of pediatric MB tumour patients after one year, three years, five years, and ten years according to case studies. From 22 June 2009 to 19 December 2019, a total of 22 patients ranging in age from 1 to 14 years old underwent tumour removal. These patients were followed to determine survival rate. Tumours were classified into three pathological subtypes: The first was classic MB, the second was desmoplastic nodular MB and MB with extensive nodularity, and the third was large cell and anaplastic MB. Patients who were 3 years old or older had a better survival rate than younger patients (log-rank test; p = 0.01). The survival probability in the older children group (55%) was significant compared to the group of younger children (29%). The Kaplan–Meier survival curves of the patients were significantly different. The ten-year survival rates in the average- and high-risk groups were 64.4% and 86.0%, respectively. After a follow-up of 120 months (median range = 60 months), recurrence or progression was observed in 22 patients and 15 patients were still alive. The estimated 10-year overall survival rates for all patients were 49.36 ± 38.33. MB patients’ survival rate was quite good in our hospital. More than half of the patients, most of whom had large cell anaplastic and classic type MB, survived the 10-year follow-up period without any problems.</p>
</abstract>

Brain tumours are the most common solid tumours that afflict the pediatric population. Me-dulloblastoma (MB) is the most common malignant brain tumour in children, constituting nearly 20% of all pediatric brain tumours. This study is an evaluation of overall survival rate of pediatric MB tumour patients after one year, three years, five years, and ten years according to case studies. From 22 June 2009 to 19 December 2019, a total of 22 patients ranging in age from 1 to 14 years old underwent tumour removal. These patients were followed to determine survival rate. Tumours were classified into three pathological subtypes: The first was classic MB, the second was desmoplastic nodular MB and MB with extensive nodularity, and the third was large cell and anaplastic MB. Patients who were 3 years old or older had a better survival rate than younger patients (log-rank test; p = 0.01). The survival probability in the older children group (55%) was significant compared to the group of younger children (29%). The Kaplan–Meier survival curves of the patients were significantly different. The ten-year survival rates in the average- and high-risk groups were 64.4% and 86.0%, respectively. After a follow-up of 120 months (median range = 60 months), recurrence or progression was observed in 22 patients and 15 patients were still alive. The estimated 10-year overall survival rates for all patients were 49.36 ± 38.33. MB patients’ survival rate was quite good in our hospital. More than half of the patients, most of whom had large cell anaplastic and classic type MB, survived the 10-year follow-up period without any problems.

Survival Study in Pediatric Patients with Medulloblastoma in a General Hospital in Tehran, Iran

Forum of Clinical Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Brain tumours are the most common solid tumours that afflict the pediatric population. Me-dulloblastoma (MB) is the most common malignant brain tumour in...

		Frequency	%
Without recurrence	Alive,	17	77.3
Recurrence	After 2 years	2	9.1
	After 4 months	2	9.1
	After 9 months	1	4.5
	Total	22	100.0

		Frequency	%
Cause	Brain death, disease-related	1	4.54
	Infection	1	4.54
	Death due to progression	2	9.09
	Tumour regrowth and fever and seizures	1	4.54
	Tumour regrowth between brain and cerebellum	1	4.54
	Upper gastrointestinal bleeding	1	4.54
	Total	7	31.79

Factor	Medulloblastoma No.	%
Age (years), range	8 (1–14)
Gender
Male	13	59.09
Female	9	40.90
Clinical presentation
Headache	17	77.2
Vomiting	18	81.8
Lack of balance	10	45.4
Vision problems	4	18.1
Dizziness	5	22.7
Anaesthesia of the hands and feet	1	4.5
Follow-up time (M ± SD)	49.36 ± 38.33
Pathological type
Classic	13	59.09
Desmoplastic	1	4.50
Large cell/anaplastic	8	36.30
Tumour size (M ± SD)	2.88 ± 1.319
Tumour location
Cerebellum	15	68.1
Posterior fossa	3	13.6
Fourth ventricle	3	13.6
Brain stem	1	4.5
Tumour size before surgery, cm
< 3	13	59.09
≥ 3	9	40.90
Chemotherapy
Yes	19	86.3
No	3	13.6
End of follow-up
status
Deceased	7	31.8
Alive	15	68.1

Survival Study in Pediatric Patients with Medulloblastoma in a General Hospital in Tehran, Iran

Article Category: Research Article

Data publikacji: 04 lip 2022

Zakres stron: 34 - 39

Otrzymano: 24 wrz 2020

Przyjęty: 22 kwi 2021

DOI: https://doi.org/10.2478/fco-2021-0004

Słowa kluczowe
Medulloblastoma, pediatrics, survival, brain tumours

© 2021 Sahel Valadan Tahbaz et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

Figure 2

Recurrence of patients.

Cause of death.

Patient characteristics (n = 22).

Survival Study in Pediatric Patients with Medulloblastoma in a General Hospital in Tehran, Iran

Article Category: Research Article

Data publikacji: 04 lip 2022

Zakres stron: 34 - 39

Otrzymano: 24 wrz 2020

Przyjęty: 22 kwi 2021

DOI: https://doi.org/10.2478/fco-2021-0004

Słowa kluczoweMedulloblastoma, pediatrics, survival, brain tumours

© 2021 Sahel Valadan Tahbaz et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

Figure 2

Recurrence of patients.

Cause of death.

Patient characteristics (n = 22).

Słowa kluczowe
Medulloblastoma, pediatrics, survival, brain tumours